Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Avidity Biosciences, Inc. (RNA) since 2020 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Avidity Biosciences, Inc.. Table 2 shows the detailed insider transactions. This company's CIK number is 1599901.
Total stock buying since 2020: $36,900,000.
Total stock sales since 2020: $89,903,331.
Total stock option exercises since 2020: $15,382,459.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2025 | 0 | $0 | 657,459 | $27,170,191 | 411,388 | $5,781,417 |
| 2024 | 0 | $0 | 1,561,578 | $54,894,324 | 1,196,568 | $9,291,219 |
| 2023 | 0 | $0 | 70,000 | $1,677,075 | 70,000 | $86,799 |
| 2022 | 0 | $0 | 170,000 | $3,792,069 | 170,000 | $178,668 |
| 2021 | 800,000 | $14,400,000 | 87,022 | $2,369,672 | 50,000 | $44,356 |
| 2020 | 1,250,000 | $22,500,000 | 0 | $0 | 0 | $0 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2025-09 | 0 | $0 | 188 | $8,914 | 0 | $0 |
| 2025-08 | 0 | $0 | 486,704 | $21,917,220 | 347,888 | $4,832,801 |
| 2025-06 | 0 | $0 | 26,786 | $876,079 | 25,875 | $382,218 |
| 2025-05 | 0 | $0 | 5,875 | $190,326 | 5,875 | $97,818 |
| 2025-03 | 0 | $0 | 94,486 | $2,906,356 | 25,875 | $370,762 |
| 2025-02 | 0 | $0 | 5,875 | $188,916 | 5,875 | $97,818 |
| 2025-01 | 0 | $0 | 37,545 | $1,082,380 | 0 | $0 |
| 2024-12 | 0 | $0 | 115,899 | $3,874,927 | 49,000 | $894,780 |
| 2024-11 | 0 | $0 | 28,323 | $1,168,496 | 28,323 | $359,620 |
| 2024-10 | 0 | $0 | 122,500 | $5,771,545 | 122,500 | $2,862,475 |
| 2024-09 | 0 | $0 | 223,937 | $9,369,483 | 126,500 | $2,736,565 |
| 2024-08 | 0 | $0 | 33,000 | $1,439,773 | 33,000 | $40,920 |
| 2024-07 | 0 | $0 | 33,000 | $1,343,166 | 33,000 | $40,920 |
| 2024-06 | 0 | $0 | 600,517 | $22,550,367 | 437,245 | $1,332,359 |
| 2024-05 | 0 | $0 | 108,000 | $2,985,619 | 108,000 | $702,420 |
| 2024-04 | 0 | $0 | 53,000 | $1,391,261 | 33,000 | $40,920 |
| 2024-03 | 0 | $0 | 228,641 | $4,850,161 | 226,000 | $280,240 |
| 2024-01 | 0 | $0 | 14,761 | $149,526 | 0 | $0 |
| 2023-02 | 0 | $0 | 60,000 | $1,457,045 | 60,000 | $74,399 |
| 2023-01 | 0 | $0 | 10,000 | $220,030 | 10,000 | $12,400 |
| 2022-12 | 0 | $0 | 40,000 | $880,560 | 40,000 | $49,600 |
| 2022-08 | 0 | $0 | 130,000 | $2,911,509 | 130,000 | $129,068 |
| 2021-11 | 0 | $0 | 25,000 | $697,225 | 25,000 | $22,125 |
| 2021-08 | 800,000 | $14,400,000 | 0 | $0 | 0 | $0 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-09-02 | Gallagher Kathleen P. (Chief Program Officer) | Sale | 188 | 47.42 | 8,914 |
| 2025-08-28 | Boyce Sarah (President and CEO) | Sale | 25,000 | 49.39 | 1,234,700 |
| 2025-08-28 | Boyce Sarah (President and CEO) | Option Ex | 25,000 | 1.24 | 31,000 |
| 2025-08-22 | Hughes Steven George (Chief Medical Officer) | Sale | 2,208 | 46.41 | 102,462 |
| 2025-08-22 | Hughes Steven George (Chief Medical Officer) | Option Ex | 2,208 | 10.16 | 22,433 |
| 2025-08-15 | Mccarthy Teresa (Chief Human Resources Officer) | Sale | 10,000 | 46.56 | 465,630 |
| 2025-08-15 | Mccarthy Teresa (Chief Human Resources Officer) | Option Ex | 10,000 | 22.34 | 223,400 |
| 2025-08-13 | Hughes Steven George (Chief Medical Officer) | Sale | 1,542 | 46.66 | 71,949 |
| 2025-08-13 | Hughes Steven George (Chief Medical Officer) | Option Ex | 1,542 | 6.57 | 10,130 |
| 2025-08-06 | Hughes Steven George (Chief Medical Officer) | Sale | 81,434 | 42.74 | 3,480,244 |
| 2025-08-06 | Hughes Steven George (Chief Medical Officer) | Option Ex | 47,451 | 13.79 | 654,349 |
| 2025-08-06 | Mosbrooker Eric (Chief Commercial Officer) | Sale | 130,807 | 44.06 | 5,763,748 |
| 2025-08-06 | Mosbrooker Eric (Chief Commercial Officer) | Option Ex | 124,687 | 9.05 | 1,128,417 |
| 2025-08-06 | Wilson Troy Edward (Director) | Sale | 95,054 | 45.00 | 4,277,430 |
| 2025-08-06 | Wilson Troy Edward (Director) | Option Ex | 29,500 | 12.26 | 361,522 |
| 2025-08-06 | Maclean Michael F (Chief Financial Officer) | Sale | 30,914 | 42.73 | 1,320,831 |
| 2025-08-06 | Levin Arthur A (Director) | Sale | 107,500 | 47.62 | 5,118,935 |
| 2025-08-06 | Levin Arthur A (Director) | Option Ex | 107,500 | 22.34 | 2,401,550 |
| 2025-08-04 | Moriarty John B (Chief Legal Officer) | Sale | 2,245 | 36.21 | 81,291 |
| 2025-06-17 | Gallagher Kathleen P. (Chief Program Officer) | Sale | 911 | 30.24 | 27,548 |
| 2025-06-11 | Flanagan W. Michael (Chief Scientific Officer) | Sale | 20,000 | 32.88 | 657,700 |
| 2025-06-11 | Flanagan W. Michael (Chief Scientific Officer) | Option Ex | 20,000 | 14.22 | 284,400 |
| 2025-06-02 | Gallagher Kathleen P. (Chief Program Officer) | Sale | 5,875 | 32.48 | 190,831 |
| 2025-06-02 | Gallagher Kathleen P. (Chief Program Officer) | Option Ex | 5,875 | 16.65 | 97,818 |
| 2025-05-01 | Gallagher Kathleen P. (Chief Program Officer) | Sale | 5,875 | 32.40 | 190,326 |
| 2025-05-01 | Gallagher Kathleen P. (Chief Program Officer) | Option Ex | 5,875 | 16.65 | 97,818 |
| 2025-03-20 | Mccarthy Teresa (Chief Human Resources Officer) | Sale | 7,778 | 31.06 | 241,584 |
| 2025-03-20 | Flanagan W. Michael (Chief Scientific Officer) | Sale | 11,780 | 31.06 | 365,863 |
| 2025-03-20 | Hughes Steven George (Chief Medical Officer) | Sale | 9,578 | 31.06 | 297,492 |
| 2025-03-20 | Boyce Sarah (President and CEO) | Sale | 31,540 | 31.06 | 979,569 |
| 2025-03-20 | Maclean Michael F (Chief Financial Officer) | Sale | 7,935 | 31.05 | 246,421 |
| 2025-03-11 | Flanagan W. Michael (Chief Scientific Officer) | Sale | 20,000 | 30.13 | 602,620 |
| 2025-03-11 | Flanagan W. Michael (Chief Scientific Officer) | Option Ex | 20,000 | 14.22 | 284,400 |
| 2025-03-03 | Gallagher Kathleen P. (Chief Program Officer) | Sale | 5,875 | 29.41 | 172,807 |
| 2025-03-03 | Gallagher Kathleen P. (Chief Program Officer) | Option Ex | 5,875 | 14.70 | 86,362 |
| 2025-02-03 | Gallagher Kathleen P. (Chief Program Officer) | Sale | 5,875 | 32.16 | 188,916 |
| 2025-02-03 | Gallagher Kathleen P. (Chief Program Officer) | Option Ex | 5,875 | 16.65 | 97,818 |
| 2025-01-22 | Gallagher Kathleen P. (Chief Program Officer) | Sale | 5,629 | 30.16 | 169,776 |
| 2025-01-21 | Gallagher Kathleen P. (Chief Program Officer) | Sale | 3,782 | 28.59 | 108,138 |
| 2025-01-21 | Mccarthy Teresa (Chief Human Resources Officer) | Sale | 2,959 | 28.59 | 84,612 |
| 2025-01-21 | Flanagan W. Michael (Chief Scientific Officer) | Sale | 5,672 | 28.59 | 162,185 |
| 2025-01-21 | Hughes Steven George (Chief Medical Officer) | Sale | 3,947 | 28.59 | 112,856 |
| 2025-01-21 | Boyce Sarah (President and CEO) | Sale | 10,397 | 28.59 | 297,291 |
| 2025-01-21 | Maclean Michael F (Chief Financial Officer) | Sale | 3,287 | 28.59 | 93,985 |
| 2025-01-21 | Levin Arthur A (Director) | Sale | 1,872 | 28.60 | 53,537 |
| 2024-12-18 | Mccarthy Teresa (Chief Human Resources Officer) | Sale | 11,151 | 32.66 | 364,191 |
| 2024-12-18 | Flanagan W. Michael (CSTO) | Sale | 12,742 | 32.66 | 416,153 |
| 2024-12-18 | Boyce Sarah (President and CEO) | Sale | 31,855 | 32.66 | 1,040,384 |
| 2024-12-18 | Maclean Michael F (Chief Financial Officer) | Sale | 11,151 | 32.66 | 364,191 |
| 2024-12-16 | Mccarthy Teresa (Chief Human Resources Officer) | Sale | 25,000 | 33.26 | 831,600 |
| 2024-12-16 | Mccarthy Teresa (Chief Human Resources Officer) | Option Ex | 25,000 | 14.22 | 355,500 |
| 2024-12-11 | Flanagan W. Michael (CSTO) | Sale | 24,000 | 35.77 | 858,408 |
| 2024-12-11 | Flanagan W. Michael (CSTO) | Option Ex | 24,000 | 22.47 | 539,280 |
| 2024-11-19 | Levin Arthur A (Director) | Sale | 3,323 | 42.12 | 139,971 |
| 2024-11-19 | Levin Arthur A (Director) | Option Ex | 3,323 | 1.24 | 4,120 |
| 2024-11-18 | Mccarthy Teresa (Chief Human Resources Officer) | Sale | 25,000 | 41.14 | 1,028,525 |
| 2024-11-18 | Mccarthy Teresa (Chief Human Resources Officer) | Option Ex | 25,000 | 14.22 | 355,500 |
| 2024-10-21 | Levin Arthur A (Director) | Sale | 5,000 | 46.63 | 233,170 |
| 2024-10-21 | Levin Arthur A (Director) | Option Ex | 5,000 | 1.24 | 6,200 |
| 2024-10-16 | Mccarthy Teresa (Chief Human Resources Officer) | Sale | 25,000 | 48.52 | 1,213,000 |
| 2024-10-16 | Mccarthy Teresa (Chief Human Resources Officer) | Option Ex | 25,000 | 14.22 | 355,500 |
| 2024-10-07 | Thompson Tamar (Director) | Sale | 30,000 | 44.98 | 1,349,250 |
| 2024-10-07 | Thompson Tamar (Director) | Option Ex | 30,000 | 27.63 | 828,900 |
| 2024-10-01 | Flanagan W. Michael (CSTO) | Sale | 62,500 | 47.62 | 2,976,125 |
| 2024-10-01 | Flanagan W. Michael (CSTO) | Option Ex | 62,500 | 26.75 | 1,671,875 |
| 2024-09-23 | Mccarthy Teresa (Chief Human Resources Officer) | Sale | 13,153 | 44.00 | 578,732 |
| 2024-09-23 | Flanagan W. Michael (CSTO) | Sale | 25,000 | 43.95 | 1,098,675 |
| 2024-09-23 | Boyce Sarah (President and CEO) | Sale | 32,880 | 44.00 | 1,446,720 |
| 2024-09-23 | Maclean Michael F (Chief Financial Officer) | Sale | 11,510 | 44.00 | 506,440 |
| 2024-09-19 | Levin Arthur A (Director) | Sale | 5,000 | 45.73 | 228,660 |
| 2024-09-19 | Levin Arthur A (Director) | Option Ex | 5,000 | 1.24 | 6,200 |
| 2024-09-11 | Mccarthy Teresa (Chief Human Resources Officer) | Sale | 25,000 | 40.40 | 1,010,050 |
| 2024-09-11 | Mccarthy Teresa (Chief Human Resources Officer) | Option Ex | 25,000 | 14.22 | 355,500 |
| 2024-09-11 | Flanagan W. Michael (CSTO) | Sale | 111,394 | 40.40 | 4,500,206 |
| 2024-09-11 | Flanagan W. Michael (CSTO) | Option Ex | 96,500 | 24.61 | 2,374,865 |
| 2024-08-19 | Levin Arthur A (Director) | Sale | 5,000 | 45.19 | 225,945 |
| 2024-08-19 | Levin Arthur A (Director) | Option Ex | 5,000 | 1.24 | 6,200 |
| 2024-08-06 | Boyce Sarah (President and CEO) | Sale | 28,000 | 43.35 | 1,213,828 |
| 2024-08-06 | Boyce Sarah (President and CEO) | Option Ex | 28,000 | 1.24 | 34,720 |
| 2024-07-19 | Levin Arthur A (Director) | Sale | 5,000 | 45.01 | 225,070 |
| 2024-07-19 | Levin Arthur A (Director) | Option Ex | 5,000 | 1.24 | 6,200 |
| 2024-07-09 | Boyce Sarah (President and CEO) | Sale | 28,000 | 39.93 | 1,118,096 |
| 2024-07-09 | Boyce Sarah (President and CEO) | Option Ex | 28,000 | 1.24 | 34,720 |
| 2024-06-20 | Levin Arthur A (Director) | Sale | 5,000 | 37.59 | 187,950 |
| 2024-06-20 | Levin Arthur A (Director) | Option Ex | 5,000 | 1.24 | 6,200 |
| 2024-06-18 | Mccarthy Teresa (Chief Human Resources Officer) | Sale | 9,864 | 39.13 | 385,968 |
| 2024-06-18 | Flanagan W. Michael (CSTO) | Sale | 10,106 | 39.13 | 395,447 |
| 2024-06-18 | Boyce Sarah (President and CEO) | Sale | 32,074 | 39.13 | 1,255,055 |
| 2024-06-18 | Maclean Michael F (Chief Financial Officer) | Sale | 11,228 | 39.13 | 439,340 |
| 2024-06-14 | Boyce Sarah (President and CEO) | Sale | 35,767 | 40.08 | 1,433,469 |
| 2024-06-14 | Boyce Sarah (President and CEO) | Option Ex | 35,767 | 1.24 | 44,351 |
| 2024-06-13 | Boyce Sarah (President and CEO) | Sale | 164,233 | 40.08 | 6,581,801 |
| 2024-06-13 | Boyce Sarah (President and CEO) | Option Ex | 164,233 | 1.24 | 203,648 |
| 2024-06-13 | Levin Arthur A (Director) | Sale | 60,000 | 40.08 | 2,404,800 |
| 2024-06-12 | Boyce Sarah (President and CEO) | Sale | 100,000 | 35.73 | 3,572,999 |
| 2024-06-12 | Boyce Sarah (President and CEO) | Option Ex | 100,000 | 1.24 | 124,000 |
| 2024-06-12 | Maclean Michael F (Chief Financial Officer) | Sale | 104,245 | 35.72 | 3,723,110 |
| 2024-06-12 | Maclean Michael F (Chief Financial Officer) | Option Ex | 104,245 | 8.82 | 919,440 |
| 2024-06-12 | Levin Arthur A (Director) | Sale | 40,000 | 35.07 | 1,402,640 |
| 2024-06-04 | Boyce Sarah (President and CEO) | Sale | 28,000 | 27.42 | 767,788 |
| 2024-06-04 | Boyce Sarah (President and CEO) | Option Ex | 28,000 | 1.24 | 34,720 |
| 2024-05-20 | Levin Arthur A (Director) | Sale | 5,000 | 29.90 | 149,480 |
| 2024-05-20 | Levin Arthur A (Director) | Option Ex | 5,000 | 1.24 | 6,200 |
| 2024-05-14 | Maclean Michael F (Chief Financial Officer) | Sale | 75,000 | 28.28 | 2,121,075 |
| 2024-05-14 | Maclean Michael F (Chief Financial Officer) | Option Ex | 75,000 | 8.82 | 661,500 |
| 2024-05-07 | Boyce Sarah (President and CEO) | Sale | 28,000 | 25.54 | 715,064 |
| 2024-05-07 | Boyce Sarah (President and CEO) | Option Ex | 28,000 | 1.24 | 34,720 |
| 2024-04-19 | Levin Arthur A (Director) | Sale | 5,000 | 22.82 | 114,125 |
| 2024-04-19 | Levin Arthur A (Director) | Option Ex | 5,000 | 1.24 | 6,200 |
| 2024-04-03 | Levin Arthur A (Director) | Sale | 20,000 | 27.11 | 542,220 |
| 2024-04-02 | Boyce Sarah (President and CEO) | Sale | 28,000 | 26.25 | 734,916 |
| 2024-04-02 | Boyce Sarah (President and CEO) | Option Ex | 28,000 | 1.24 | 34,720 |
| 2024-03-19 | Levin Arthur A (Director) | Sale | 5,000 | 23.97 | 119,850 |
| 2024-03-19 | Levin Arthur A (Director) | Option Ex | 5,000 | 1.24 | 6,200 |
| 2024-03-12 | Boyce Sarah (President and CEO) | Sale | 28,000 | 22.63 | 633,696 |
| 2024-03-12 | Boyce Sarah (President and CEO) | Option Ex | 28,000 | 1.24 | 34,720 |
| 2024-03-12 | Levin Arthur A (Director) | Sale | 27,641 | 22.02 | 608,599 |
| 2024-03-12 | Levin Arthur A (Director) | Option Ex | 25,000 | 1.24 | 31,000 |
| 2024-03-08 | Boyce Sarah (President and CEO) | Sale | 84,000 | 21.39 | 1,796,676 |
| 2024-03-08 | Boyce Sarah (President and CEO) | Option Ex | 84,000 | 1.24 | 104,160 |
| 2024-03-01 | Boyce Sarah (President and CEO) | Sale | 84,000 | 20.14 | 1,691,340 |
| 2024-03-01 | Boyce Sarah (President and CEO) | Option Ex | 84,000 | 1.24 | 104,160 |
| 2024-01-22 | Mccarthy Teresa (Chief Human Resources Officer) | Sale | 2,065 | 10.13 | 20,918 |
| 2024-01-22 | Flanagan W. Michael (CSTO) | Sale | 4,129 | 10.13 | 41,826 |
| 2024-01-22 | Boyce Sarah (President and CEO) | Sale | 5,092 | 10.13 | 51,581 |
| 2024-01-22 | Maclean Michael F (Chief Financial Officer) | Sale | 1,616 | 10.13 | 16,370 |
| 2024-01-22 | Levin Arthur A (Director) | Sale | 1,859 | 10.13 | 18,831 |
| 2023-02-14 | Levin Arthur A (Chief Scientific Officer) | Sale | 10,000 | 23.93 | 239,310 |
| 2023-02-14 | Levin Arthur A (Chief Scientific Officer) | Option Ex | 10,000 | 1.24 | 12,400 |
| 2023-02-03 | Boyce Sarah (President and CEO) | Sale | 3,221 | 24.26 | 78,141 |
| 2023-02-03 | Boyce Sarah (President and CEO) | Option Ex | 3,221 | 1.24 | 3,994 |
| 2023-02-02 | Boyce Sarah (President and CEO) | Sale | 45,879 | 24.36 | 1,117,750 |
| 2023-02-02 | Boyce Sarah (President and CEO) | Option Ex | 45,879 | 1.24 | 56,889 |
| 2023-02-01 | Boyce Sarah (President and CEO) | Sale | 900 | 24.27 | 21,844 |
| 2023-02-01 | Boyce Sarah (President and CEO) | Option Ex | 900 | 1.24 | 1,116 |
| 2023-01-12 | Levin Arthur A (Chief Scientific Officer) | Sale | 10,000 | 22.00 | 220,030 |
| 2023-01-12 | Levin Arthur A (Chief Scientific Officer) | Option Ex | 10,000 | 1.24 | 12,400 |
| 2022-12-29 | Levin Arthur A (Chief Scientific Officer) | Sale | 40,000 | 22.01 | 880,560 |
| 2022-12-29 | Levin Arthur A (Chief Scientific Officer) | Option Ex | 40,000 | 1.24 | 49,600 |
| 2022-08-25 | Boyce Sarah (President and CEO) | Sale | 14,855 | 23.07 | 342,689 |
| 2022-08-25 | Boyce Sarah (President and CEO) | Option Ex | 14,855 | 1.24 | 18,420 |
| 2022-08-24 | Boyce Sarah (President and CEO) | Sale | 35,045 | 22.80 | 798,920 |
| 2022-08-24 | Boyce Sarah (President and CEO) | Option Ex | 35,045 | 1.24 | 43,455 |
| 2022-08-16 | Levin Arthur A (Chief Scientific Officer) | Sale | 3,499 | 22.08 | 77,257 |
| 2022-08-16 | Levin Arthur A (Chief Scientific Officer) | Option Ex | 3,499 | 1.24 | 4,338 |
| 2022-08-15 | Boyce Sarah (President and CEO) | Sale | 100 | 22.47 | 2,247 |
| 2022-08-15 | Boyce Sarah (President and CEO) | Option Ex | 100 | 1.24 | 124 |
| 2022-08-15 | Levin Arthur A (Chief Scientific Officer) | Sale | 62,498 | 22.12 | 1,382,330 |
| 2022-08-15 | Levin Arthur A (Chief Scientific Officer) | Option Ex | 62,498 | .89 | 55,310 |
| 2022-08-12 | Levin Arthur A (Chief Scientific Officer) | Sale | 14,003 | 22.00 | 308,066 |
| 2022-08-12 | Levin Arthur A (Chief Scientific Officer) | Option Ex | 14,003 | .53 | 7,421 |
| 2021-11-18 | Levin Arthur A (Chief Scientific Officer) | Sale | 25,000 | 27.89 | 697,225 |
| 2021-11-18 | Levin Arthur A (Chief Scientific Officer) | Option Ex | 25,000 | .89 | 22,125 |
| 2021-08-04 | Wong Roderick (MP and CIO) | Buy | 800,000 | 18.00 | 14,400,000 |
| 2021-06-25 | Levin Arthur A (Chief Scientific Officer) | Sale | 20,100 | 28.55 | 573,955 |
| 2021-06-25 | Levin Arthur A (Chief Scientific Officer) | Option Ex | 20,100 | .89 | 17,788 |
| 2021-06-24 | Levin Arthur A (Chief Scientific Officer) | Sale | 100 | 27.75 | 2,775 |
| 2021-06-24 | Levin Arthur A (Chief Scientific Officer) | Option Ex | 100 | 1.24 | 124 |
| 2021-06-17 | Levin Arthur A (Chief Scientific Officer) | Sale | 200 | 27.75 | 5,550 |
| 2021-06-17 | Levin Arthur A (Chief Scientific Officer) | Option Ex | 200 | 1.24 | 248 |
| 2021-06-15 | Levin Arthur A (Chief Scientific Officer) | Sale | 23,019 | 26.02 | 599,069 |
| 2021-06-14 | Levin Arthur A (Chief Scientific Officer) | Sale | 14,003 | 25.92 | 362,915 |
| 2021-03-16 | Levin Arthur A (Chief Scientific Officer) | Sale | 4,600 | 27.87 | 128,183 |
| 2021-03-16 | Levin Arthur A (Chief Scientific Officer) | Option Ex | 4,600 | .89 | 4,071 |
| 2020-06-16 | Cormorant Private Healthcare Fund Ii, Lp | Buy | 300,000 | 18.00 | 5,400,000 |
| 2020-06-16 | Wong Roderick (Director) | Buy | 950,000 | 18.00 | 17,100,000 |
Insider trading activities including stock purchases, stock sales, and option exercises of RNA listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Avidity Biosciences, Inc. (symbol RNA, CIK number 1599901) see the Securities and Exchange Commission (SEC) website.